I den store subgruppe af patienter, som gennemgik cancerkirurgi (69% af patienterne), var forekomsten af VTE 4, 7% i fondaparinuxgruppen mod 7, 7% i dalteparingruppen.
In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.